View source for Pegylated interferon-alpha-2b

{{drugbox
| IUPAC_name = PEGylated human interferon alpha 2b
| image = 
| CAS_number = 99210-65-8
| ATC_prefix = L03
| ATC_suffix = AB10
| ATC_supplemental = 
| PubChem = 
| DrugBank = BTD00048
| C=860 | H=1353 | N=229 | O=255 | S=9
| molecular_weight = 19269.1 g/mol
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 22-60 hrs
| excretion = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_UK = <!-- GSL / P / POM / CD -->
| legal_US = <!-- OTC / Rx-only -->
| legal_status = 
| routes_of_administration = 
}}
{{CMG}}
__NOTOC__


==Overview==

'''[[Pegylated]] [[interferon]] alfa-2b''' is a treatment for [[hepatitis C]] developed by Schering-Plough, brand name is Peg Intron.

It was approved in January 2001.

==External links==
* [http://www.fda.gov/cder/biologics/products/pegsche011901.htm"FDA Approval Information"]
* [http://www.pegintron.com"Peg Intron Website"]
* [http://news.bbc.co.uk/2/hi/health/6224601.stm "Medicines patent loophole 'found'" at bbc.co.uk]

{{Interferons}}

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}